STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery Disease
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery Disease
-
Narrated by:
-
By:
About this listen
Patients with peripheral artery disease (PAD) often experience significant walking difficulties, and there are limited therapies available to improve their mobility. Investigation made through the STRIDE (Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease) trial focused on semaglutide, a drug known for promoting weight loss, reducing inflammation, and lowering the risk of heart attack or stroke, to determine if it could enhance the functional abilities of PAD patients.
In this interview, Drs. Alison Bailey and Marc Bonaca discuss how the STRIDE trial data supports the use of semaglutide for individuals with PAD and type 2 diabetes, highlighting its cardiometabolic, cardiovascular, and kidney benefits, as well as its ability to improve function, symptoms, and overall quality of life.
Subscribe on Apple Podcasts | Subscribe to ACCEL